Sitemap
Update: July 26th, 2009
Sitemap of posts on Orshe.com
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
Posts
- Category: Wall Street Journal (continued)
- A.M. Vitals: Bird-Flu Study Released Despite Terrorism Concerns
- A.M. Vitals: Breast Cancer Awareness, Twitter Research and Japan’s Contested Pharma Market
- A.M. Vitals: Breast Cancer Research Covers Radiation Treatment
- A.M. Vitals: Bristol-Myers Paying $2.5 Billion For Inhibitex
- A.M. Vitals: Bristol-Myers Squibb and Pfizer End One Study of Blood Thinner
- A.M. Vitals: Bristol-Myers Squibb to Pay $735 Million for ZymoGenetics
- A.M. Vitals: Buffett’s Berkshire Hathaway Raises Johnson & Johnson Stake
- A.M. Vitals: Caffeine Associated With Lower Risk of Depression in Women
- A.M. Vitals: California Health-Insurance Rates Draw Scrutiny — Again
- A.M. Vitals: Cancer Death Rates Falling
- A.M. Vitals: Cancer Drugs By Bristol and Novartis May Top Gleevec
- A.M. Vitals: Cardiac Resynchronization Devices May Not Help 38% of Patients
- A.M. Vitals: Case Claiming Individual Mandate is Unconstitutional to Proceed
- A.M. Vitals: China Halts Sale of Some Drugs
- A.M. Vitals: Cholera Likely to Spread in Haitian Capital
- A.M. Vitals: Chronic Diseases Could Cost $30 Trillion By 2030
- A.M. Vitals: Chronic Fatigue Syndrome Patients, Researchers Clash
- A.M. Vitals: Cigarette Companies Sue to Prevent Graphic Package Warnings
- A.M. Vitals: Cigna Eyes Individual Market If Overhaul Makes it Attractive
- A.M. Vitals: Cigna Pushes Overseas, Seeking Growth
- A.M. Vitals: Cigna’s 2nd-Quarter Profit Falls 32%, Beats Expectations
- A.M. Vitals: Cigna’s First-Quarter Profit Rises 52%
- A.M. Vitals: Cities Grapple With Medical Pot; No Need for ‘Octomom’ Restrictions?
- A.M. Vitals: Coca-Cola Found Fungicide in OJ From Brazil
- A.M. Vitals: Colorado Cantaloupes Linked to Listeria
- A.M. Vitals: Colorado Farm Recalling Cantaloupes on Listeria Fears
- A.M. Vitals: Community Health Systems Drops Bid for Tenet Healthcare
- A.M. Vitals: Companies Look to Test Cancer-Drug Combos
- A.M. Vitals: Confusion Over XMRV-Chronic Fatigue Syndrome Continues
- A.M. Vitals: Congress is Back, and So is Health-Care Debate
- A.M. Vitals: Consequences of Mental-Health Parity Law
- A.M. Vitals: Could Genzyme Attract Other Suitors?
- A.M. Vitals: Court Rejects Medical-Test Patents
- A.M. Vitals: Crucell’s Manufacturing Problems Resolved
- A.M. Vitals: CVS Blames Computer Error for Price Snafu
- A.M. Vitals: CVS Paying $1.25 Billion to Expand Medicare Part D Business
- A.M. Vitals: CVS to Pay $5 Million to Settle FTC Charges
- A.M. Vitals: Daiichi Sankyo, GlaxoSmithKline Form Vaccine Venture
- A.M. Vitals: Dannon to Pay $21 Million to Settle Probiotics Complaints
- A.M. Vitals: Data For J&J’s Zytiga Support Wider Use
- A.M. Vitals: Deep-Brain Stimulation Tested For Memory Problems
- A.M. Vitals: Diabetes Treatment Found to Work Relatively Poorly in Children
- A.M. Vitals: Diet Drugs a Tough Road For Developers, Investors
- A.M. Vitals: Disappointment for HIV Pill Study in Women
- A.M. Vitals: Doctors Fear Squeeze as Reimbursement Schemes Evolve
- A.M. Vitals: Does Jell-O Cause Hyperactivity?
- A.M. Vitals: Drug Kills Fat Cells in Monkeys; Human Trials May Be Next
- A.M. Vitals: Drugs Linked to Hospitalizations in Seniors
- A.M. Vitals: Dueling Proposals to Extract Savings from Medicare
- A.M. Vitals: E. coli Outbreak In Europe Kills 14
- A.M. Vitals: E. coli Strain in Europe is ‘Unique,’ WHO Says
- A.M. Vitals: E.U. Backs Roche’s Avastin for Breast Cancer
- A.M. Vitals: Elan Reports Own Director to SEC
- A.M. Vitals: Employers’ Health-Care Premiums Rose 9% This Year
- A.M. Vitals: Endo to Pay About $2.6 Billion for American Medical Systems
- A.M. Vitals: EPA Recommends Schools Replace Lights to Avoid PCBs
- A.M. Vitals: Express Scripts to Buy Medco For $29 Billion
- A.M. Vitals: Express Scripts Will Make Changes to Lipitor Coverage
- A.M. Vitals: Express Scripts, Medco Defend Proposed Merger to Congress
- A.M. Vitals: Extended Breast Feeding, Obesity Drug and Heart Devices
- A.M. Vitals: Eye Care Helps Novartis See 12% Increase in 2Q Net Profit
- A.M. Vitals: Fake Avastin Case Puts Overseas Drug Suppliers In Focus
- A.M. Vitals: Fake Avastin Turned Up in Syria in 2009
- A.M. Vitals: FDA Adds a Warning, Removes Another From Statin Labels
- A.M. Vitals: FDA Advisory Panel Approves Wider Use of Lilly’s Cymbalta
- A.M. Vitals: FDA Advisory Panel Backs Lower Dose of Novartis Lung Drug
- A.M. Vitals: FDA Advisory Panel Votes Against Drugs as Prostate-Cancer Preventatives
- A.M. Vitals: FDA Advisory Panel Votes Against Novartis’s Gout Drug
- A.M. Vitals: FDA and CDC Say Baby Formula Not Contaminated
- A.M. Vitals: FDA Appeals Panel to Hold Avastin Hearing This Week
- A.M. Vitals: FDA Approves Ella, a Longer-Acting ‘Morning-After’ Pill
- A.M. Vitals: FDA Approves Glaxo, Human Genome Sciences Lupus Drug
- A.M. Vitals: FDA Approves Johnson & Johnson HIV Drug
- A.M. Vitals: FDA Approves Merck Drug for Glaucoma
- A.M. Vitals: FDA Approves Targeted Melanoma Treatment From Roche, Daiichi
2009 -